Phase 1 Study With Sorafenib and Sirolimus

Inclusion Criteria:

* Patients with histological or cytological confirmed advanced solid tumor, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a combination of sorafenib and sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer, hormone refractory prostate cancer).
* Men or women of at least 18 years
* Patients who have an ECOG status of 0 or 1
* Patients who have a life expectancy of at least 12 weeks
* Adequate bone marrow, liver and renal function
* Negative pregnancy test for female patients of childbearing potential
* Women and men enrolled into this trial must use adequate birth control measures during the course of the trial.
* Signed informed consent

Exclusion Criteria:

* History of serious cardiac disease
* Active clinically serious bacterial, viral or fungal infections (\> grade 2).
* Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
* Clinically symptomatic brain or meningeal metastasis.
* Patients with seizure disorders requiring medication (such as steroids or antiepileptics).
* Patients with evidence or history of bleeding diathesis.
* Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results.
* Concomitant treatment with strong CYP3A4 inductors (such as rifampicin, St. John´s Wort) or CYP3A4 inhibitors (such as ketoconazole, voriconazole, itraconazole, diltiazem, verapamil, erythromycin). Moderate or weak CYP3A4 modifiers should be used concomitantly only after careful assessment of risk-benefit ratio. Concomitant use of carbamazepine, phenobarbital, phenytoin or chronic use of dexamethasone is excluded